Asahi Kasei Bioprocess is a global provider of bioprocess solutions focused on enhancing the safety, efficiency, and purity of biologics and pharmaceutical manufacturing. It specializes in virus removal filtration, fluid management equipment, clarification and purification products, biosafety testing services, and contract development and manufacturing organization (CDMO) capabilities.
Core products include the Planova™ series of virus removal filters (such as Planova™ 15N, 20N, 35N, BioEX, S20N, and FG1), BioOptimal™ microfilters for clarification, and advanced fluid management systems like inline buffer formulation and chromatography equipment. It also offers pathogen safety testing through acquired entities such as ViruSure and Bionique, along with plasmid DNA and biologics CDMO services via Bionova Scientific.
The business operates worldwide with key facilities and sales offices in Japan (Nobeoka and Tokyo), the United States (Glenview, Illinois, and Texas), Europe (Belgium and Germany), and China (Shanghai and Suzhou). It maintains a strong position as a market leader in virus filtration technology for biotherapeutics, supporting antibody drugs, plasma derivatives, nucleic acid drugs, and emerging modalities like cell and gene therapies.
Asahi Kasei Bioprocess functions as the bioprocess division of Asahi Kasei Life Science Corp., established in 2025 as a core operating company within the Asahi Kasei Group. Asahi Kasei Corp. serves as the holding company, with the group emphasizing healthcare as a key growth sector. This structure leverages the parent company's expertise in fibers, chemicals, and materials to deliver reliable, innovative solutions to pharmaceutical manufacturers globally.
Also known as 旭化成バイオプロセス, AKB, and Planova Division.
Automated single‑use benchtop virus filtration for lab‑scale and process development; supports Planova 35N filters and will be shown at BPI East (Booth 606).
